e-learning
resources
Glasgow 2004
Monday 06.09.2004
Chemotherapy, targeted therapies costs and outcomes
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Cisplatin/vinorelbine remains a valid option for the front-line chemotherapy of NSCLC
G. Buccheri, D. Ferrigno, M. C. Giordano (Cuneo, Italy)
Source:
Annual Congress 2004 - Chemotherapy, targeted therapies costs and outcomes
Session:
Chemotherapy, targeted therapies costs and outcomes
Session type:
Thematic Poster Session
Number:
1939
Disease area:
Thoracic oncology
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
G. Buccheri, D. Ferrigno, M. C. Giordano (Cuneo, Italy). Cisplatin/vinorelbine remains a valid option for the front-line chemotherapy of NSCLC. Eur Respir J 2004; 24: Suppl. 48, 1939
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
ERS clinical practice guidelines on treatment of sarcoidosis
Related content which might interest you:
Neoadjuvant chemotherapy for NSCLC, lung function and surgical therapy – which is their connection?
Source: International Congress 2019 – Lung function testing: from experimental investigations to clinical applications
Year: 2019
What outcome after the prescription of neoadjuvant chemotherapy in lung cancer?
Source: Annual Congress 2011 - Instructive clinical aspects of lung cancer
Year: 2011
Adjuvant and neoadjuvant therapy in nonsmall cell lung cancer (NSCLC)
Source: Annual Congress 2006 - Clinical year in review
Year: 2006
Definitive radiation therapy for elderly patients with stage III NSCLC not candidates for combined chemoradiation
Source: Annual Congress 2012 - Treatment of lung cancer
Year: 2012
Impact of neoadjuvant therapies on surgical indications and early postoperative outcome
Source: Annual Congress 2005 - Multidisciplinary treatment of non-metastatic non-small cell lung cancer: contemporary concepts
Year: 2005
Adjuvant therapy in NSCLC
Source: Annual Congress 2007 - Clinical year in review
Year: 2007
Bevacizumab shows survival benefit for non-small lung cancer patients who received subsequent pemetrexed treatment but not had a therapeutic effect in clinical practice
Source: Annual Congress 2012 - Treatment of lung cancer
Year: 2012
Palliative chemotherapy in non-small cell lung cancer (NSCLC): first-line therapy data from the ACTION observational study
Source: Annual Congress 2005 - Chemotherapy and palliative care
Year: 2005
The big lung trial (BLT): determining the value of cisplatin-based chemotherapy for all patients with non-small cell lung cancer (NSCLC). Preliminary results in the radical radiotherapy setting
Source: Eur Respir J 2003; 22: Suppl. 45, 163s
Year: 2003
Early stage nonsmall-cell lung cancer: therapeutic options (surgery, adjuvant and neoadjuvant therapy)
Source: Annual Congress 2011 - PG10 Management of thoracic tumours in practice: a HERMES basic course
Year: 2011
Combination of neoadjuvant and adjuvant chemotherapy in marginally resectable IIIA nonsmall cell lung cancer (NSCLC): long-term follow up
Source: Eur Respir J 2006; 28: Suppl. 50, 772s
Year: 2006
Combined modality treatment for NSCLC
Source: Annual Congress 2007 - PG7 - Thoracic oncology: nonsmall cell lung cancer
Year: 2007
Use of 2
nd
-line polychemotherapy in advanced nonsmall cell lung cancer – a reasonable approach
Source: Eur Respir J 2003; 22: Suppl. 45, 65s
Year: 2003
Treatment of potentially resectable locoregional (stage III) non-small cell lung cancer
Source: Annual Congress 2005 - PG2 - Lung cancer: non-small cell lung cancer treatment
Year: 2005
Single agent gemcitabine or docetaxel in the second-line therapy for patients with non-small cell lung cancer previously treated with platin-based chemotherapy
Source: Annual Congress 2013 –Systemic therapy of lung cancer and quality of life
Year: 2013
Symptomatic benefit of short regimen of palliative radiotherapy for elderly patients with locally advanced non small cell lung cancer
Source: Annual Congress 2010 - Treatment of lung cancer
Year: 2010
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept